protoporphyrin ix has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awazu, K; Fujino, T; Hazama, H; Kaneda, Y; Kannen, H | 1 |
| Chen, L; Dong, C; Han, Y; Hu, X; Liang, S; Lin, Y; Liu, J; Lu, Y; Shi, S; Wang, C; Yao, T; Zhou, L | 1 |
2 other study(ies) available for protoporphyrin ix and docetaxel anhydrous
| Article | Year |
|---|---|
Development of laser ionization techniques for evaluation of the effect of cancer drugs using imaging mass spectrometry.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Photosensitizing Agents; Protoporphyrins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Taxoids; Zeolites | 2014 |
Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Survival; Copper; Docetaxel; Drug Carriers; Folic Acid; Humans; Immunotherapy; Lasers; Mice; Nanocomposites; Oligonucleotides; Phototherapy; Polyethyleneimine; Protoporphyrins; Reactive Oxygen Species; T-Lymphocytes, Cytotoxic; Triple Negative Breast Neoplasms | 2019 |